Press Releases

Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced that Company management is scheduled to present at the 18th Annual Rodman & Renshaw Global Investment Conference, being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY. During the presentation,…read more →

Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced results from a preclinical study demonstrating that the synergistic effect of its lead signal-interfering DNA product candidate AsiDNA™ in combination with various products in the PARP (PolyADP-Ribose Polymerase) inhibitor…read more →

Onxeo Reports First-Half 2016 Business Update and Consolidated Financials

- Expansion of orphan oncology pipeline through acquisition of DNA Therapeutics and lead compound AsiDNATM - Important development milestones on existing assets: Livatag® Phase III trial in HCC: 80% of patients randomized First development steps of the new oral formulation of Beleodaq® - Board reinforced with high-profile pharma business and scientific experts and establishment of US subsidiary in New York City - €19.6M…read more →

Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America

Agreement covering seven South American countries Onxeo to receive upfront payment, regulatory and commercial milestones, and sales royalties for a total deal value greater than USD 20 million Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced it has entered into an exclusive license agreement…read more →

Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives // DANISH TRANSLATION: Onxeo samarbejder med Royal College of Surgeons i Irland om forskningsprogram vedrørende derivater af Beleodaq®

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced a collaboration with the Royal College of Surgeons in Ireland (RCSI) for a discovery-stage program on the derivatives of belinostat (Beleodaq®), a histone deacetylase (HDAC) inhibitor. This new collaboration program aims…read more →

Onxeo receives USPTO Notice of Allowance for key AsiDNA™ patent, extending IP protection in the U.S. until 2031 // DANISH TRANSLATION: Onxeo modtager “Notice of Allowance” fra de amerikanske patentmyndigheder for det primære AsiDNA™ patent, hvilket forlænger patentbeskyttelsen i USA indtil 2031

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair signal interfering technology and products protected by 8 patent families worldwide  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapies, today…read more →

Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA // DANISH TRANSLATION: Onxeo offentliggør udviklingsplan for det innovative signal-interfererende DNA-produkt AsiDNA

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Near- and mid term expected milestones  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), an innovative company specializing in the development of orphan oncology therapeutics, today announced its plan for further development of AsiDNA, its first-in-class signal interfering DNA molecule which breaks the cycle of tumor DNA…read more →

Onxeo announces development of Beleodaq® oral formulation opening new opportunities for its HDAC inhibitor // DANISH TRANSLATION: Onxeo offentliggør udviklingen af en oral formulering af Beleodaq®, som åbner nye muligheder for selskabets HDAC-hæmmer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. The company has obtained the first set of positive results of PK study with new oral formulation of Beleodaq®  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the first set of positive results from a preclinical pharmacokinetic (PK)…read more →

Publication of 2015 Reference Document // DANISH TRANSLATION: Offentliggørelse af Reference Document for 2015

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the publication of the Company’s 2015 Reference Document. The 2015 Reference Document, registered with the French Market Authorities (Autorité des Marchés Financiers) on April 29, 2016, is available to the…read more →

Onxeo First Quarter 2016 Financial Information and Business Update // DANISH TRANSLATION: Onxeo informerer om sine resultater og forretningsmæssige tiltag i 1. kvartal 2016

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today provided an update on financial results and major milestones achieved during the first quarter of 2016, ending March…read more →

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment // DANISH TRANSLATION: Endelige data fra mekanistisk studie med Livatag® viser foretrukken affinitet for leveren, hvilket understøtter brugen til behandling af fremskreden HCC

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today reported the final data from a study aiming to confirm the mechanism…read more →

Passing on Onxeo’s Extraordinary and Ordinary General Meeting // DANISH TRANSLATION: Forløb af Onxeos ekstraordinære og ordinære generalforsamling

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that the Extraordinary and Ordinary General Meeting, held at the company’s headquarters in Paris, France on April 6, 2016, adopted all of the resolutions recommended by the Board of Directors….read more →

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC // DANISH TRANSLATION: Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark),  – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III…read more →

Onxeo announces closing of DNA Therapeutics acquisition // DANISH TRANSLATION: Onxeo gennemfører opkøbet af DNA Therapeutics

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has completed the acquisition of DNA Therapeutics and its signal-interfering DNA (siDNA) repair technology and lead product…read more →

Onxeo Announces Establishment of U.S. Subsidiary // DANISH TRANSLATION: Onxeo etablerer amerikansk datterselskab

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Pharmaceutical and biotech industry veteran, Philippe Maitre, to head U.S subsidiary Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the creation of a U.S. subsidiary, based in New York City. The company also announced that experienced industry executive…read more →